---
schema_version: "secwatch.filing_event.v1"
accession: "0001720580-26-000060"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-09-28T12:15:31+00:00"
generated_at: "2026-10-12T13:31:09.939765+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet prula-cel Phase 1: 50% CRR in lupus nephritis at 12 months, 54% DORIS remission; pivotal study to start Q4 2026

## Summary
- 22 efficacy-evaluable patients (16 lupus nephritis, 6 extra-renal SLE) with 6-21 months follow-up; 13 patients had at least 12 months of follow-up.
- At 12 months, 50% of evaluable LN patients achieved a complete renal response and 54% achieved DORIS remission; all 12-month responses ongoing at 12-21 months except 1 patient.
- Safety: no CRS greater than Grade 2, Grade 1/2 CRS in 25%, no DLTs, IEC-HS or ICANS; infections in 54% (Grade 3+ 8.3%); no GvHD; FDA-aligned profile supports outpatient dosing.
- All patients discontinued immunosuppressants and all but one tapered steroids to 5 mg or less prednisone equivalent; 22/22 achieved undetectable CD19+ B cells with naive-dominant reconstitution.
- FDA-aligned single-arm pivotal LN study (inadequate response to 2+ immunosuppressants; primary endpoint CRR at 12 months) start-up in Q4 2026; data updates H1 2027 (SSc) and mid-2027 (LN/SLE).

## SEC filing metadata
- accession: 0001720580-26-000060
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-09-28T12:15:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/0001720580-26-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000060/acet-20260928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001720580-26-000060
- JSON: https://secwatch.observer/filing/0001720580-26-000060.json
- Plain text: https://secwatch.observer/filing/0001720580-26-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.